IL6 and neoplasm: Remarkably, CPD-L1 plus AZA combination therapy could significantly upregulate the levels of IFN-γ, IL-12p70, TNF-α, and downregulate the levels of IL-6, IL-10 in tumor tissues (Fig. 7F).